Literature DB >> 8806558

Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation.

J Paintsil1, M Müller, M Picken, L Gissmann, J Zhou.   

Abstract

The papillomavirus major capsid protein L1 can assemble into capsids in vitro. To identify areas within the bovine papillomavirus type-1 L1 (BPV L1) protein that are important for virus assembly, we constructed a set of 24 baculovirus recombinants expressing BPV L1 deletion mutants that span the entire L1 open reading frame. Virus-like particle (VLP) formation of the L1 mutants was examined by electron microscopy. Wild-type (wt) BPV L1 expressed in recombinant baculovirus formed VLPs, while capsomeres and aggregates were seen for most of the mutants screened. However, the C-terminal truncation mutant, lacking the last 24 amino acids (delta C2), was observed to form VLPs (threefold more efficiently than wt BPV L1). This suggests that this C-terminal region of L1 protein is not critical for capsid formation. As capsids assembled from BPV L1 are able to agglutinate mouse red blood cells (RBC) by binding to a membrane protein, we tested the ability of the mutants to hemagglutinate mouse RBCs. Most aberrant capsids or aggregates derived from deletion mutants were unable to agglutinate the RBCs with the exception of deletion mutants delta 11 (aa 231-271), delta 14 (aa 291-331), delta 21 (aa 431-471), and the carboxyl-terminus truncation mutant delta C2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806558     DOI: 10.1006/viro.1996.0473

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Assembly and translocation of papillomavirus capsid proteins.

Authors:  Luise Florin; Cornelia Sapp; Rolf E Streeck; Martin Sapp
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70.

Authors:  Luise Florin; Katrin A Becker; Cornelia Sapp; Carsten Lambert; Hüseyin Sirma; Martin Müller; Rolf E Streeck; Martin Sapp
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.

Authors:  Yougang Zhai; Zhenyu Zhong; Mohammadreza Zariffard; Gregory T Spear; Liang Qiao
Journal:  Vaccine       Date:  2013-09-19       Impact factor: 3.641

4.  Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses.

Authors:  W Shi; J Liu; Y Huang; L Qiao
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.

Authors:  M P McCarthy; W I White; F Palmer-Hill; S Koenig; J A Suzich
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 6.  Cervical cancer screening.

Authors:  Dorothy J Wiley; Bradley J Monk; Emmanuel Masongsong; Kristina Morgan
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

7.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles.

Authors:  Katrin A Becker; Luise Florin; Cornelia Sapp; Gerd G Maul; Martin Sapp
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Oral immunogenicity of human papillomavirus-like particles expressed in potato.

Authors:  Heribert Warzecha; Hugh S Mason; Christopher Lane; Anders Tryggvesson; Edward Rybicki; Anna-Lise Williamson; John D Clements; Robert C Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.

Authors:  Hongtao Zhang; Raja Fayad; Xilin Wang; Daniel Quinn; Liang Qiao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.